Illumina shares fall 11.48% intraday as analysts cut price targets amid Q4 results.

Illumina Inc. (ILMN) fell 11.48% in intraday trading following a sharp selloff after its Q4 2025 earnings report. The decline accelerated negative momentum from an 8.13% after-hours drop, driven by mixed analyst reactions and investor skepticism. While the company exceeded earnings and revenue estimates, analysts cut price targets—Evercore reduced its target to $150 from $155, and UBS raised its target to $135 but highlighted a broader "Hold" consensus. The earnings call emphasized clinical growth and margin expansion but failed to alleviate concerns over long-term valuation pressures and competitive dynamics, as noted in analyst reports. Despite Stifel maintaining a "Buy" rating, the stock’s sharp intraday decline suggests market participants prioritized bearish sentiment over positive earnings surprises.